Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Journey Medical Corporation (DERM)

NCM · Drug Manufacturers - Specialty & Generic

$6.31-0.06 (-0.94%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$173.7M
P/E (TTM)
EPS
$-0.37
Div Yield
52W Range
$4.31–$9.55
Beta
1.07

Company overview

Next earnings: 2026-08-11(14d)

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Peers in Drug Manufacturers - Specialty & Generic

All in industry →

Recent press releases

April 2026

3 months ago8-KHealthcare

DERM secures third GPO deal, expanding Emrosi coverage to 150 million lives

DERMJourney Medical Corp

# 📜 What This Document Is 📄 This document is an 8-K filing, which is an important, timely filing used to announce material events to the public. Think of it like a company issuing an urgent press release through the SEC. It tells investors and the market what happened *today* that could significa

Read summaryView on SEC EDGAR

SEC filings

All filings →
1 recent filing shown in the timeline above. View all SEC filings →

Journey Medical Corporation has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
798,366 sh● NEW
457,812 sh● NEW
251,436 sh● NEW
444,642 sh+94.5%
764,147 sh+24.2%
290,226 sh+99.8%
1,854,596 sh0.0%
719,784 sh+13.7%

People at Journey Medical Corporation

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$13.1M
NI -$4.1M
06/25
$735.0K
NI -$3.8M
09/25
$17.6M
NI -$2.3M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.09
Prior: $-0.16
Revenue sparkline
DERM (NCM) Stock Quote, Press Releases & SEC... | Cayman Journal | Cayman Journal